StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Aerie Pharma (AERI): Raising PT On Roclatan Data - Needham
May 25, 2017 6:17 AM
Needham & Company analyst, Serge Belanger, reiterated his Buy rating on shares of Aerie Pharma (NASDAQ: AERI) and raised his ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst PT Change
Next Articles
Aerie Pharma (AERI) PT Raised to $70 at Aegis Capital Following Phase III Trial
May 25, 2017 8:24 AM